Released Aug 7, 2025, after the close
10-Q filed Aug 8, 2025, 39 days after period end · 0000950170-25-105284
Q2 2025 · 10-Q
Revenue—
Net Income-$2.44M-$2.44M N/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$28.04-$28.04 N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$2,461,229N/M
Operating Cash Flowderived-$1,919,281N/M
What the release said
The release
Same quarter
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Net Income | -$2.44M | -$8.39M | -$1.45M | -$1.83M |
| EPS Diluted | -$28.04 | -$246.27 | -$5.83 | -$4.16 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Revelation Biosciences, Inc. · CIK 1810560 · Engraved from SEC EDGAR